Summary
The response makes multiple claims about availability, manufacturers, pricing, patents, and purchasing logistics. None of these are supported or assessable against the provided FDA label excerpts, which only cover clinical indications, dosing, contraindications, warnings/precautions, adverse reactions, and drug interactions.
Category Scores
Accurate Statements
Generic rosuvastatin (the active ingredient in CRESTOR) is used for high cholesterol.
Label excerpt indicates CRESTOR is an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia (Indications and Usage 1).
Unsupported Statements
Generic rosuvastatin has been available since 2016 after AstraZeneca's patents expired.
Patent/launch-availability timeline is not addressed in the provided CRESTOR label excerpts.
Major manufacturers of generic rosuvastatin include Mylan, Teva, and Lupin.
Manufacturer lists are not provided in the label excerpts.
Generic rosuvastatin is prescribed for high cholesterol.
While CRESTOR is indicated for hypercholesterolemia, the response frames this as generic rosuvastatin being prescribed; the label excerpts do not describe generic prescribing or whether generic products follow label indications.
Generic rosuvastatin is FDA-approved as equivalent to brand-name Crestor.
FDA approval/ANDA equivalence statements are not present in the provided label excerpts.
Bulk purchases of generic rosuvastatin often reduce the per-pill cost through discounts or wholesale pricing.
Pricing/wholesale/discount claims are not addressed in the label excerpts.
A 30-day supply (30 tablets) of 10 mg generic rosuvastatin costs $10–$25 at retail pharmacies.
Retail pricing amounts are not provided in the label excerpts.
A 90-day or 100-tablet bulk pack of generic rosuvastatin drops to $20–$50, or about $0.20–$0.50 per pill.
Bulk pricing amounts are not provided in the label excerpts.
Prices for generic rosuvastatin vary by pharmacy (including Walmart, Costco, and GoodRx), dosage (5 mg–40 mg), and location.
Pharmacy-specific pricing and location variability are not addressed in the label excerpts.
Online bulk purchases from sites like Costco or HealthWarehouse can save 20–50% over single prescriptions, especially with coupons.
Discount/coupon savings and specific sites are not addressed in the label excerpts.
Costco Pharmacy offers 90-day supplies of generic rosuvastatin for $15–$30, with membership required.
Specific retail pricing and membership requirements are not addressed in the label excerpts.
Walmart and Sam's Club match similar pricing for generic rosuvastatin bulk options.
Specific retailer pricing and matching claims are not addressed in the label excerpts.
GoodRx lists bulk deals starting at $12 for 90 tablets of generic rosuvastatin.
GoodRx-specific pricing claims are not addressed in the label excerpts.
Amazon Pharmacy and HealthWarehouse ship larger quantities of generic rosuvastatin (e.g., 500 tablets) with free shipping on bulk orders.
Specific seller logistics (quantities, shipping, free shipping) are not addressed in the label excerpts.
BJ's Wholesale and Sam's Club provide 100+ tablet bottles of generic rosuvastatin at 30–40% below retail.
Specific packaging/quantity and discount percentage claims are not addressed in the label excerpts.
Online/mail-order drug purchasing requires verification of prescription requirements and state laws.
Regulatory/purchasing workflow requirements are not provided in the label excerpts.
Brand Crestor prices for 30 tablets (10 mg) are approximately $300–$400.
Brand drug pricing amounts are not provided in the label excerpts.
Generic rosuvastatin prices for 30 tablets (10 mg) are approximately $10–$25.
Pricing amounts are not provided in the label excerpts.
Brand Crestor prices for 90 tablets (10 mg) are approximately $900+.
Pricing amounts are not provided in the label excerpts.
Generic rosuvastatin prices for 90 tablets (10 mg) are approximately $20–$50.
Pricing amounts are not provided in the label excerpts.
Generic rosuvastatin prices for 500 tablets (bulk) are approximately $80–$150.
Pricing amounts are not provided in the label excerpts.
AstraZeneca's key patents for Crestor expired in 2016, enabling generics.
Patent timeline is not addressed in the provided label excerpts.
Remaining pediatric exclusivity for Crestor ended in 2022.
Exclusivity/pediatric exclusivity dates are not addressed in the provided label excerpts.
No major patent disputes block current generics of Crestor.
Patent dispute status is not addressed in the provided label excerpts.
Formulation patents (e.g., for specific coatings) for Crestor exist until 2026–2030.
Patent life details are not addressed in the provided label excerpts.
The referenced formulation patents do not affect standard tablets.
Patent effect on formulation/availability is not addressed in the provided label excerpts.
Contradictions
Important Omissions
If the response intends to describe prescribing and safe use, it does not include label-relevant elements such as contraindications (acute liver failure/decompensated cirrhosis; hypersensitivity), key warnings/precautions (myopathy/rhabdomyolysis risk factors; hepatic dysfunction; HbA1c/glucose increases), and dosage instructions (5–40 mg once daily; missed dose guidance; antacid separation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is primarily about availability and pricing rather than dosing/safety. However, it omits label-based safety-critical information; because it is not providing dosing/administration instructions, direct harm from incorrect dosing claims is unlikely based on the provided content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are unrelated to FDA-approved prescribing information and cannot be verified from the provided label excerpts (pricing, patents, manufacturers, and purchasing logistics).
Suggested Improvement
Limit claims to label-supported clinical information (indications, dosing/administration, contraindications, warnings/precautions, drug interactions, and relevant patient populations) and avoid unverifiable market/pricing/patent details unless supported by the provided label text.